Inventiva (IVA)
(Delayed Data from NSDQ)
$2.42 USD
-0.18 (-6.92%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $2.40 -0.02 (-0.83%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Inventiva S.A. Sponsored ADR [IVA]
Reports for Purchase
Showing records 1 - 20 ( 81 total )
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
FY2023 Recap; LPFV in NATiV3 Trial On Target in 1H24; LEGEND Shows Key Data in T2D Patients With MASH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
LEGEND Interim Data in T2D Patients With MASH Are Broadly Positive; Phase 3 NATiV3 LPFV On Target in 1H24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Voluntary Pause on Pivotal NATiV3 Lifted; Patient Screening Has Resumed; Study Timeline Unaffected; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Phase 3 NATiV3 Enrollment Temporarily Paused Due to a SUSAR Event; LPFV Now Expected in 2Q24; Moderating PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Enter a New Key Challenger in the MASH Race: Sagimet''s Denifanstat Looks to Enter Phase 3 by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Topline Results of Phase 3 NATiV3 Study Delayed Another Six Months to 1H26; Other Business Updates; Reduce PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
1H23 Recap; We Continue to Expect NATiV3''s Top-line Readout in 2H25; Adding Major Asian Markets to Our Model; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Lanifibranor Enters Two Sizable NASH Markets With Partnership; NATiV3''s LPFV in 2H23 As Next Milestone; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Hepalys Agreement Expands lani Opportunity into Japan and South Korea
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
NATiV3 Trial Now 50% Enrolled With LPFV Expected in 2H23; T2D Status Could Be a Key Baseline Factor; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
EASL Congress 2023: Day 3 and Day 4 NASH Highlights
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
EASL updates reveal all things going well for lanifibranor in NASH
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Lanifibranor Shows Impressive Cardiometabolic Benefits and Glycemic Control in Patients With NAFLD and T2D; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Inventiva S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Positive Phase 2 NAFLD/T2D Results Reinforce Favorable View on Lani
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D